Figure 1
The complexity of IL-6 signaling gives insight into why blockade of IL-6 (via, for example, SIL) or IL-6R (via, for example, TCZ) alone may not be sufficient to decrease IL-6-mediated signal transduction to a clinically relevant extent in COVID-19-related ARDS.